CPS
  • Home

Head & Neck Cancer

PD-L1 IHC 28-8 pharmDx Interpretation Training for Squamous Cell Carcinoma of the Head and Neck (SCCHN)​

This three-part self-paced learning program will enable you to confidently interpret PD-L1 expression​ (≥ 1% tumor cell expression) utilizing PD-L1 IHC 28-8 pharmDx. Detection of PD-L1 expressing tumor cells in SCCHN patient specimens may indicate an enhanced survival benefit from nivolumab.​

    Duration 2h
  • Interactive
  • Foundational
 SaveSave UnsaveUnsave

What you will learn​

 

The PD-L1 IHC 28-8 pharmDx interpretation training is a comprehensive program with in-depth content and practice cases focused on helping pathologists to:​

  • Understand the role of immune checkpoint pathways​
  • Learn about technical considerations for optimal slide staining results​
  • Learn how to evaluate squamous cell carcinoma of the head and neck (SCCHN) specimens, stained with PD-L1 IHC 28-8 pharmDx​

 

​Review the Intended Use for PD-L1 IHC 28-8 pharmDx SK005.

Related Training

This website addresses general principles for CDx scoring and is for education purposes only. Not all cancer indications mentioned are approved worldwide. Please refer to local Instructions for Use for further details.​D0113483_1.00